TRT benefits vs. hype: what the evidence actually shows

What did @dr_carlossanchez actually say?

The creator argues that testosterone's Schedule III classification, born out of 1990s and 2000s doping concerns, now creates unnecessary barriers for men and women who are genuinely deficient. He says regulators are already re-evaluating access, and closes by inviting viewers to get tested at his clinic.

That's a reasonable enough framing, but the pitch ends with a direct patient acquisition line targeting tired working parents. The video blends legitimate policy commentary with what amounts to a clinic advertisement, and viewers should hold both parts to different standards of scrutiny.

Does the science back this up?

The historical claim is mostly accurate. The scheduling argument has real merit. The implied list of benefits, energy, cognition, mood, body composition, is where the evidence gets a lot messier than a TikTok caption can capture.

Testosterone was placed on Schedule III under the Anabolic Steroids Control Act of 1990, expanded in 2004, partly in response to athletic doping concerns. That history is not disputed. On whether rescheduling is appropriate, there is genuine policy debate. The FDA has faced ongoing pressure from patient advocates and some clinicians who argue the controlled substance designation delays prescribing and creates pharmacy access issues for legitimate hypogonadism patients.

On benefits: testosterone does improve lean mass, sexual function, and bone density in men with confirmed hypogonadism. Bhasin et al. (2010, New England Journal of Medicine) remains a foundational trial here. For mood and cognition, the evidence is far weaker and more heterogeneous. The TRAVERSE trial (Lincoff et al., 2023, NEJM) found no significant cardiovascular harm in men with hypogonadism, which was reassuring, but it also did not find dramatic quality-of-life benefits across all measured domains.

For women, the evidence base is even thinner. Off-label use is common, but there are no FDA-approved testosterone products for women in the United States as of 2024.

What did they get wrong (or right)?

Credit where it's due: the scheduling history is accurate, and raising access barriers as a policy question is legitimate. Saying testosterone therapy is being re-evaluated by regulators is also factually grounded, though vague.

What's wrong, or at least incomplete, is the implied universality of testosterone deficiency symptoms. The creator lists energy, strength, cognition, mood, and body composition as things testosterone addresses. These are real symptoms of confirmed hypogonadism. But "running around all day long" tired is not a clinical diagnosis. Fatigue and low energy have dozens of causes, most of which are not low testosterone. Thyroid dysfunction, sleep apnea, depression, iron deficiency, and simple overwork all mimic low-T symptoms and are far more common in the general population.

Framing a fatigued working parent as a candidate for testosterone testing without any discussion of differential diagnosis is not dangerous by itself, but it is incomplete in a way that benefits the clinic selling the test. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) are explicit that testosterone therapy should only be initiated in men with both consistently low serum levels and unambiguous symptoms, not just symptoms alone.

What should you actually know?

Testosterone's Schedule III status is a real policy issue, but it does not mean everyone who is tired needs a testosterone workup. Confirmed hypogonadism has a specific clinical definition, and testing without that clinical context leads to a lot of borderline results being treated aggressively.

If you are genuinely symptomatic, getting tested is reasonable. But a single total testosterone number is not the whole picture. Free testosterone, SHBG, LH, and FSH all matter. Time of day at collection matters. Two separate morning measurements are standard before any treatment decision, per current guidelines.

For women, the lack of FDA-approved testosterone products means any prescribing is off-label. That does not make it wrong, but it does mean the evidence base is thinner and the dosing standards are less established. The Global Consensus Position Statement on testosterone use in women (Davis et al., 2019, Journal of Clinical Endocrinology and Metabolism) supports use for hypoactive sexual desire disorder but is more cautious on broader symptom claims.

The rescheduling conversation is worth having. Access barriers for confirmed patients are a legitimate clinical concern. But that conversation should not be doing double duty as a clinic marketing pitch on TikTok.